 | Up a level |
de Stefano, Nicola; Barkhof, Frederik; Montalban, Xavier; Achiron, Anat; Derfuss, Tobias; Chan, Andrew; Hodgkinson, Suzanne; Prat, Alexandre; Leocani, Letizia; Schmierer, Klaus; Sellebjerg, Finn; Vermersch, Patrick; Wiendl, Heinz; Keller, Birgit; Roy, Sanjeev (2022). Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS. Neurology: neuroimmunology & neuroinflammation, 9(4), e1187. Wolters Kluwer Health 10.1212/NXI.0000000000001187
Coles, Alasdair J; Jones, Joanne L; Vermersch, Patrick; Traboulsee, Anthony; Bass, Ann D; Boster, Aaron; Chan, Andrew; Comi, Giancarlo; Fernández, Óscar; Giovannoni, Gavin; Kubala Havrdova, Eva; LaGanke, Christopher; Montalban, Xavier; Oreja-Guevara, Celia; Piehl, Fredrik; Wiendl, Heinz; Ziemssen, Tjalf (2022). Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple sclerosis journal, 28(5), pp. 842-846. Sage 10.1177/13524585211061335
